Pharmacology Book

http://www.fpnotebook.com/

CelecoxibAka: Celebrex

Advertisement

  1. Class
    1. NSAID: COX2 Inhibitor
    2. Similar to Rofecoxib (Vioxx)
    3. Diaryl-substituted pyrazole
  2. Advantages
    1. Less gastrointestinal adverse effects than other NSAIDs
      1. See NSAID Gastrointestinal Adverse Effects
  3. Metabolism
    1. Oral Bioavailability: 22 to 40%
    2. Half Life: 11 hours
    3. Liver metabolism by Cytochrome P450: CYP2C9
      1. Levels raised with Accolate, Diflucan, and Lescol
    4. Inhibits Cytochrome P450: CYP2D6
      1. Increases levels of Beta Blockers and psychotropics
  4. Contraindications: Sulfonamide allergy
    1. Consider alternative agent: Rofecoxib (Vioxx)
  5. Dosing
    1. Osteoarthritis: 200 mg PO qd (or 100 mg po bid)
    2. Rheumatoid Arthritis: 200 mg PO qd to bid
    3. Familial Adenoma Polyposis: 400 mg PO bid
  6. Adverse Effects
    1. See COX-2 Inhibitor for Nonfatal risk
    2. Abdominal Pain
    3. Diarrhea
    4. Dyspepsia
    5. Peptic Ulcer Disease risk (see COX2 Inhibitor)
    6. Does not increase Bleeding Time
  7. References
    1. Michalets (1998) Pharmacotherapy 18:84
    2. (1999) Med Lett Drugs Ther 41(1045):11

celecoxib (C0538927)

Definition (NCI)A drug that reduces pain. Celecoxib belongs to the family of drugs called nonsteroidal anti-inflammatory agents. It is being studied for cancer prevention.
Definition (PDQ)A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43023&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43023&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1728" NCI Thesaurus)
Definition (NCI)A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.
ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
MSHC105934
Englishcelecoxib, CELECOXIB PREPARATION, Celecoxib product
Spanishproducto con celecoxib
Parent ConceptsCyclooxygenase Inhibitors (C0085387), Sulfonamides (C0038760), [MS102] NONSALICYLATE NSAIS, ANTIRHEUMATIC (C0973575), Cyclooxygenase 2 Inhibitors (C1257954), Reason not stated concept (C1276325)
SourcesCSP, LNC, MSH, MTH, MTHSPL, NCI, NDFRT, PDQ, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF
Derived from the NIH UMLS (Unified Medical Language System)


Celebrex (C0719198)

ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
MSHC105934
EnglishCelebrex, Heumann brand of celecoxib, Mack brand of celecoxib, Parke Davis brand of celecoxib, Pfizer brand of celecoxib, Pharmacia brand of celecoxib, Pharmacia Spain brand of celecoxib, Searle brand of celecoxib
SourcesCSP, MSH, NCI, PDQ, RXNORM
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree